Mitochondrial inner membrane interactors of Aurora kinase A/AURKA and PHB2 shape organelle metabolic heterogeneity.

This study reveals that Aurora kinase A (AURKA) and the mitophagy receptor PHB2 form a platform of inner mitochondrial membrane interactors with respiratory chain proteins to spatially regulate ATP production and organelle architecture, thereby driving metabolic heterogeneity in cancer cells.

The Gist

The Big Picture: The Cell's Power Plant and the "Boss"

Imagine a cancer cell as a busy city. Inside this city, there are thousands of tiny power plants called mitochondria. Their job is to generate energy (ATP) to keep the city running and growing.

In healthy cities, these power plants work in a coordinated, uniform way. But in cancer, things get chaotic. The power plants start acting differently from one another—some are super-charged, some are sluggish, and some are broken. This "metabolic chaos" helps the cancer grow and survive.

The paper focuses on a specific protein called AURKA. Think of AURKA as a mischievous boss that often gets promoted (overexpressed) in cancer cells. When this boss is in charge, it doesn't just tell the power plants to work harder; it actually reorganizes the entire city's energy grid, creating a mix of high-performance and low-performance power plants. This makes the cancer cell very adaptable and hard to kill.

The Discovery: Finding the Boss's "Right-Hand Men"

The researchers wanted to know: How does this boss (AURKA) reorganize the power plants?

They discovered that AURKA doesn't work alone. It teams up with another protein called PHB2 (think of PHB2 as the boss's loyal assistant or "gatekeeper"). Together, they form a command center on the inner wall of the power plant (the inner mitochondrial membrane).

Using high-tech "proximity maps" (like a radar that detects who is standing next to whom), the team found that AURKA and PHB2 shake hands with a specific group of proteins. These proteins are the engineers and mechanics of the power plant:

• NDUFA9 & ATP5F1A/B: The main gears that actually generate the electricity.
• SLC25A13: A transporter that moves fuel (aspartate/glutamate) in and out.
• SAMM50: A construction manager that helps build the power plant's structure.

The Analogy: Imagine AURKA and PHB2 are the foremen standing on a construction site. They are holding hands with the specific workers (the proteins listed above) who are building the engine. The paper shows that when the foremen are present, they change who the workers talk to and how they build the engine.

The Twist: The Boss Changes the Blueprint, Not the Location

The researchers noticed something strange. When AURKA takes over, the power plants change shape. They swell up, clump together, and look messy. You might think this messiness causes the boss to grab different workers.

But that's not what happened.

Using super-microscopes (like looking at a city from a satellite), they saw that even though the power plants looked messy, the boss (AURKA) and the assistant (PHB2) were still standing in the exact same spot, holding hands with the same workers.

The Analogy: Imagine a construction site where the buildings are collapsing and the ground is shaking. You'd expect the foremen to run around frantically. Instead, the foremen are standing perfectly still in the same spot, calmly holding hands with the same crew, even though the building around them is falling apart. The structure is broken, but the team is intact.

The Real Culprit: Rewiring the Engine

So, if the location didn't change, what did? The connections.

When AURKA is overactive, it forces the engine workers (NDUFA9 and ATP5F1A) to swap partners. They stop talking to their usual friends and start talking to new, different proteins. This "rewiring" changes how the engine runs, creating that chaotic mix of high and low energy output (metabolic heterogeneity) that helps the cancer survive.

The Solution: The "Reset Button" (HMBB)

The researchers found a small molecule drug called HMBB. Think of HMBB as a reset button or a "peacekeeper."

When they gave HMBB to the cancer cells:

1. It stopped the boss (AURKA) from messing with the workers.
2. The engine workers went back to talking to their original, normal partners.
3. The chaotic energy grid smoothed out. The power plants started working uniformly again.

The Analogy: It's like a noisy, chaotic party where the DJ (AURKA) is playing random, jarring music. HMBB is the person who walks in, unplugs the DJ, and puts the original, smooth playlist back on. The party calms down, and everyone starts dancing in sync again.

The Single-Cell Surprise: One Worker Does It All

Finally, the researchers zoomed in on individual cells. They found that one specific worker, SLC25A13, was the key to keeping the chaos going.

• Without SLC25A13: The power plants clumped together in a corner, the energy production dropped, and the "chaotic mix" disappeared. The cell became uniform but weak.
• With SLC25A13: The power plants were spread out, and the cell maintained that dangerous mix of high and low energy zones.

The Analogy: SLC25A13 is like the traffic controller at a busy intersection. If you remove the traffic controller, all the cars (mitochondria) pile up in one spot, and traffic stops. If the controller is there, cars flow in different directions, creating a complex, busy network. The cancer needs that traffic controller to keep its energy network diverse and adaptable.

Why This Matters

This paper is a breakthrough because it identifies the specific "handshake" between the cancer boss (AURKA) and the power plant engineers.

1. It explains the "How": We now know that cancer cells create energy chaos by physically rewiring their engine parts, not just by breaking them.
2. It offers a cure: The drug HMBB can reverse this rewiring. By targeting this specific interaction, we might be able to "reset" the cancer cell's energy grid, making it vulnerable to treatment.
3. New Targets: The proteins SLC25A13, NDUFA9, and ATP5F1A are now identified as potential new targets for future cancer drugs.

In short: The researchers found the specific team of workers the cancer boss uses to break the power grid. They also found a way to break up that team, forcing the power grid to return to normal, which could help us fight cancer more effectively.

Technical Summary

1. Problem Statement

Mitochondria are critical for tumor growth, capable of flexibly rewiring their metabolic activity to support cancer progression. While it is known that metabolic heterogeneity exists both between cells and within individual cells, the signaling networks organizing this diversity remain poorly understood.

• Key Context: Aurora Kinase A (AURKA) is frequently overexpressed in breast and hematological cancers. It localizes to mitochondria and, when overexpressed, triggers mitophagy (via interaction with the receptor Prohibitin-2, PHB2), degrading part of the mitochondrial network while enhancing the metabolic capacity of the remaining organelles.
• The Gap: It was unclear how AURKA and PHB2 physically coordinate to modulate Oxidative Phosphorylation (OXPHOS) and metabolic heterogeneity at the molecular level. Specifically, the identity of the inner mitochondrial membrane (IMM) proteins that serve as a platform for this metabolic rewiring was unknown.

2. Methodology

The study employed a multi-modal approach combining proximity-dependent labeling, super-resolution microscopy, live-cell imaging, and pharmacological intervention:

• Proximity Interactomics:
  • BioID: Used to map the proximal interactome of PHB2 (fused to BirA*) in HEK293 cells.
  • TurboID: Used to map the proximal interactomes of NDUFA9 (Complex I) and ATP5F1A (Complex V) fused to TurboID in cells with or without AURKA overexpression.
  • Mass Spectrometry: Quantitative proteomics (LFQ and DIA-NN) to identify shared interactors and changes in protein abundance upon AURKA overexpression or drug treatment.
• Live-Cell Microscopy & FRET/FLIM:
  • FRET/FLIM: Used to validate physical interactions between AURKA/PHB2 and candidate IMM proteins in live MCF7 cells using GFP (donor) and mCherry (acceptor) fusions.
  • BioSenSRRF: A pipeline combining the mitoGO-ATeam2 biosensor (for ATP levels) with Enhanced Super-Resolution Radial Fluctuations (SRRF) microscopy. This allowed for the visualization of ATP production "hotspots" and "coldspots" at the single-cell level to quantify metabolic heterogeneity.
• Super-Resolution Imaging (dSTORM):
  • Direct Stochastic Optical Reconstruction Microscopy was used to assess the nanoscale colocalization of AURKA/PHB2 with IMM markers (MIC60 for cristae junctions, ATP5F1B for cristae membranes) to determine if morphological changes altered protein proximity.
• Pharmacological & Genetic Perturbation:
  • HMBB: A small molecule inhibitor targeting the AURKA/PHB2 interaction.
  • siRNA: Knockdown of specific IMM proteins (NDUFA9, SAMM50, SLC25A13, ATP5F1B) to assess functional roles in mitophagy and metabolism.
  • Cell Lines: MCF7, T47D (breast cancer), and HEK293 Flp-In T-REx.

3. Key Contributions & Results

A. Identification of a Shared IMM Interaction Platform

• The study identified a specific set of 21 mitochondrial proteins shared between AURKA and PHB2 interactomes.
• Core Interactors: Through FRET/FLIM validation, four proteins were confirmed as high-confidence shared interactors located at the IMM or IMM/OMM contact sites:
  • NDUFA9 (Complex I subunit)
  • ATP5F1A/B (Complex V subunits)
  • SAMM50 (IMM/OMM contact site/import protein)
  • SLC25A13 (Aspartate/glutamate antiporter)
• These proteins form a "platform" coupling the kinase and the mitophagy receptor to respiratory chain complexes.

B. AURKA Overexpression Rewires Interactomes Without Altering Nanoscale Proximity

• Morphology vs. Proximity: AURKA overexpression causes mitochondrial swelling and aggregation. However, dSTORM analysis revealed that these morphological changes do not alter the nanoscale proximity (colocalization) between AURKA/PHB2 and IMM markers (MIC60/ATP5F1B).
• Interactome Rewiring: Despite stable physical proximity, AURKA overexpression significantly rewires the molecular interactomes of NDUFA9 and ATP5F1A.
  • New interactions appeared involving catabolism, valine metabolism, and Complex IV assembly factors (e.g., COA1, SURF1).
  • This suggests AURKA drives metabolic diversification by recruiting new partners to existing respiratory complexes rather than simply moving them.

C. Pharmacological Restoration via HMBB

• Treatment with HMBB (an AURKA/PHB2 inhibitor) in AURKA-overexpressing cells:
  • Restored the physiological interactomes of NDUFA9 and ATP5F1A, reversing the AURKA-induced rewiring.
  • Specifically restored interactions with IMM proteins like COA1, TSPO, ATAD3B, OPA3, and NUDT8.
  • This confirms that the AURKA/PHB2 interaction is the driver of the metabolic rewiring, not just the overexpression of AURKA itself.

D. SLC25A13 Drives Metabolic Heterogeneity

• Role of SLC25A13: Knockdown of SLC25A13 in T47D cells led to:
  • Mitochondrial clustering around the perinuclear area.
  • A significant decrease in PPARGC1 (PGC-1α/β) levels, a master regulator of mitochondrial biogenesis.
  • Reduced overall mitochondrial ATP production.
• Single-Cell Heterogeneity: Using BioSenSRRF, the study showed that SLC25A13 depletion dramatically increased metabolic heterogeneity (more "hotspots" and "coldspots" of ATP production) within individual cells.
• Mechanism: SLC25A13 is required to sustain the metabolic heterogeneity induced by AURKA. Its absence mimics the effect of HMBB treatment, suggesting that SLC25A13 is a critical node in the AURKA-dependent metabolic adaptation network.

4. Significance

• Mechanistic Insight: The paper defines a specific molecular platform (AURKA/PHB2/NDUFA9/ATP5F1A/SLC25A13) that spatially organizes mitochondrial metabolism. It demonstrates that metabolic rewiring is driven by changes in protein-protein interaction networks rather than gross changes in organelle proximity.
• Metabolic Heterogeneity: It provides a mechanism for how cancer cells generate metabolic diversity within a single cell, a key factor in tumor resilience and drug resistance.
• Therapeutic Implications:
  • Validates HMBB as a tool to reverse AURKA-driven metabolic adaptation and restore physiological interactomes.
  • Identifies SLC25A13, NDUFA9, and ATP5F1A as potential therapeutic targets. Targeting these nodes could disrupt the metabolic flexibility of AURKA-overexpressing tumors.
• Methodological Advance: The integration of interactomics with single-cell super-resolution FRET (BioSenSRRF) offers a powerful pipeline for dissecting the spatial and functional heterogeneity of organelle metabolism in cancer.

In conclusion, the study establishes that AURKA and PHB2 act as a scaffold to recruit specific IMM proteins, reshaping the interactome of respiratory complexes to drive metabolic heterogeneity. Disrupting this platform (via HMBB or targeting SLC25A13) offers a promising strategy for metabolism-focused anticancer therapies.